Unfit patients even have the alternative of venetoclax plus obinutuzumab (VO) as frontline therapy. This is based on the period III demo that in contrast VO with ClbO in elderly/unfit sufferers.113 VO was superior with regard to response price and progression-absolutely free survival, and experienced a similar protection profile. In https://leonardr356gwl6.izrablog.com/profile